Scholarlink

<p>Gastric adenocarcinoma (GA) is a highly heterogeneous malignant tumor with varying biological behaviors and prognosis. Clinically, we observed some GA exhibiting dual expressions of both primitive enterocyte phenotype (PEP) and euroendocrine differentiation (NED). However, clinicopathological features of this subtype (DEGA) remain unclear. In this research, we enrolled 186 GAPEP patients and divided into DEGA (77, 41.4%) and nDEGA (109, 58.6%) by immunohistochemistry. The DEGA group demonstrated a worse prognosis than the nDEGA group (<i>P</i> = 0.03). Notably, DEGA cases had a higher incidence of nodal metastasis at early stages (T1) compared to nDEGA (50% vs. 7.1%, <i>P</i> = 0.011), and immunohistochemistry evaluation showed persistent NED traits even in metastatic nodes. NED was more prevalent in GAPEP than in nGAPEP, as evidenced by higher Synaptophysin and Chromogranin-A expressions at both the protein and mRNA levels. Human gastric cancer cell line in vitro experiments indicated a correlation between Alpha-Fetoprotein and Synaptophysin, and double knockdown of these two genes resulted in a more pronounced inhibition of proliferation. Single-cell RNA sequencing further highlighted the stemness in DEGA cells. The public datasets also affirmed above DEGA features. Neoadjuvant therapy was less effective for DEGA patients compared to those with nDEGA. Additionally, DEGA significantly differed from neuroendocrine carcinoma (NEC), lacking typical NEC morphological features, consistently expressing PEP markers, and exhibiting distinct genomic and serum marker profiles. In summary, DEGA exhibits distinct aggressive behaviors and molecular characteristics that differentiate it from other gastric adenocarcinomas, implicating it in poor prognosis and therapeutic resistance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dual-expression (primitive enterocyte phenotype and neuroendocrine differentiation) gastric adenocarcinoma: the unique high-aggressive subtype

  • 期刊论文

  • 发表日期：

    2025年8月1日

查看全文
  • Bingzhi Wang,
  • Yinong Wang,
  • Na Cheng,
  • Zhuo Li,
  • Shuai Wu,
  • Long Wang,
  • Jiaqi Xu,
  • Ziyue Wang,
  • Jiali Mu,
  • Hongying Wang,
  • Jianming Ying,
  • Liyan Xue

摘要

Gastric adenocarcinoma (GA) is a highly heterogeneous malignant tumor with varying biological behaviors and prognosis. Clinically, we observed some GA exhibiting dual expressions of both primitive enterocyte phenotype (PEP) and euroendocrine differentiation (NED). However, clinicopathological features of this subtype (DEGA) remain unclear. In this research, we enrolled 186 GAPEP patients and divided into DEGA (77, 41.4%) and nDEGA (109, 58.6%) by immunohistochemistry. The DEGA group demonstrated a worse prognosis than the nDEGA group (P = 0.03). Notably, DEGA cases had a higher incidence of nodal metastasis at early stages (T1) compared to nDEGA (50% vs. 7.1%, P = 0.011), and immunohistochemistry evaluation showed persistent NED traits even in metastatic nodes. NED was more prevalent in GAPEP than in nGAPEP, as evidenced by higher Synaptophysin and Chromogranin-A expressions at both the protein and mRNA levels. Human gastric cancer cell line in vitro experiments indicated a correlation between Alpha-Fetoprotein and Synaptophysin, and double knockdown of these two genes resulted in a more pronounced inhibition of proliferation. Single-cell RNA sequencing further highlighted the stemness in DEGA cells. The public datasets also affirmed above DEGA features. Neoadjuvant therapy was less effective for DEGA patients compared to those with nDEGA. Additionally, DEGA significantly differed from neuroendocrine carcinoma (NEC), lacking typical NEC morphological features, consistently expressing PEP markers, and exhibiting distinct genomic and serum marker profiles. In summary, DEGA exhibits distinct aggressive behaviors and molecular characteristics that differentiate it from other gastric adenocarcinomas, implicating it in poor prognosis and therapeutic resistance.